Limited coverage drugs – aztreonam
Last updated on October 7, 2022
|
Generic name |
aztreonam |
|---|---|
|
Strength |
75 mg/ml
|
| Form |
vial-neb |
|
Special Authority criteria |
Approval period |
|---|---|
|
For the cyclic treatment of chronic Pseudomonas aeruginosa infections in patients with: Moderate to severe cystic fibrosis AND A deteriorating clinical condition despite treatment with inhaled tobramycin |
Indefinite |
Practitioner exemptions
- None
Special notes
- Cyclic treatment is measured in 28-day cycles and is defined as 28 days “on” aztreonam followed by 28 days “off”
- Aztreonam may be prescribed either as monotherapy or as a combination treatment with another therapy chosen by the prescribing physician
- Aztreonam is a PharmaCare high-cost drug. PharmaCare reimburses high-cost drugs eligible for coverage to a maximum price based on the manufacturer list price plus a 5 percent mark-up